Access to Capital: Managing the Antitrust Risks Associated With Mergers and Affiliations
15 August 2013
As part of this session, we will discuss:
- Mergers and other affiliations as a common way for hospitals and health systems to access capital, and an overview of trends in this area
- The increasing scrutiny of hospital and health system mergers by regulators (FTC, principally, but also DOJ and state AGs)
- An overview of recent enforcement activity: What kinds of transactions are generating enforcement actions? What are the common threads?
- How to manage the antitrust review process
- The importance of engaging counsel and the role of protective privileges
- How to avoid the creation of deal-killing documents
- Hart-Scott-Rodino filing — when it is necessary and how to manage the process
- An assessment of the economic impact and early judgments on the likelihood of enforcement scrutiny
- What does a challenge (a second request, litigation, and so forth) look like?
- How to manage the cost and delays caused by regulatory review, and what to expect
Speakers
- Roger D. Strode, Moderator, Partner, Foley & Lardner LLP
- David W. Simon, Partner, Foley & Lardner LLP
- Alan D. Rutenberg, Partner, Foley & Lardner LLP
- Lawrence Wu, President, NERA Economic Consulting
The Access to Capital Web Conference Series provides participants with needed information in the most efficient manner possible — only a telephone line and Internet access are required to participate — allowing you to stay up-to-date with timely information from anywhere in the nation.
For more information, please visit Foley.com or contact Zulaikha Rahim at [email protected].
People
Related Insights
09 May 2024
Events
The Changing Hospital Landscape
Foley partner Larry Vernaglia, co-chair of the firm’s Providers of Health Care Services Area of Focus, is moderating a panel at the 2024 Convergence Forum titled “The Changing Hospital Landscape.”
23 April 2024
Article
U.S. Supreme Court Rules That “Pure Omissions” Are Not Actionable Under Rule 10b-5
On April 12, 2024, the United States Supreme Court delivered an important decision on the issue of whether a failure to make disclosure required under Item 303 of Regulation S-K can support a Rule 10b-5 claim, even in the absence of an otherwise-misleading statement.
23 April 2024
PharmaPatents
USPTO Issues Updated Guidance on Obviousness
For the first time in nearly 15 years, the U.S. Patent and Trademark Office has issued “Updated Guidance for Making a Proper Determination of Obviousness” under the U.S. Supreme Court’s ruling in KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007).